{"id":95447,"date":"2025-08-25T20:16:06","date_gmt":"2025-08-25T20:16:06","guid":{"rendered":"https:\/\/www.newsbeep.com\/au\/95447\/"},"modified":"2025-08-25T20:16:06","modified_gmt":"2025-08-25T20:16:06","slug":"whats-going-on-with-novo-nordisk-stock-monday-novo-nordisk-nysenvo","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/au\/95447\/","title":{"rendered":"What’s Going On With Novo Nordisk Stock Monday? – Novo Nordisk (NYSE:NVO)"},"content":{"rendered":"

The U.S. Food and Drug Administration<\/a> (FDA) has identified repeated quality control failures, including foreign particle contamination, inadequate investigations, and insufficient corrective actions at the Novo Nordisk A\/S NVO operated facility in Bloomington, Indiana.<\/p>\n

In 2024, Novo Nordisk acquired three fill-finish sites from Novo Holdings A\/S for $11 billion. The acquisition was part of a larger deal where Novo Holdings acquired Catalent, Inc. CTLT.<\/p>\n

The three sites, located in Anagni, Italy, Brussels, Belgium, and Bloomington, Indiana, specialize in the sterile filling of drugs<\/a>.<\/p>\n

Also Read: Weighing The Costs: Obesity Drug Users Make Financial Sacrifices As Coverage Tightens<\/a><\/p>\n

The company\u2019s internal records revealed multiple deviations involving extrinsic contamination, such as cat hair and unidentified particles found during 100% manual visual inspections.<\/p>\n

The problems were reported on Thursday by STAT News, which obtained a copy<\/a> of the FDA report.<\/p>\n

The production plant \u201cfailed to determine a root cause of the contamination, assess the potential impact to the rest of the lot, or evaluate whether similar issues may have occurred in upstream batches,\u201d the agency\u2019s investigator wrote.<\/p>\n

Hair contamination has been a persistent issue, with at least 20 deviations reported since July 2024.<\/p>\n

The company\u2019s deviation investigations often lacked comprehensive historical reviews, limiting searches to one year and failing to consistently include related records such as complaints, CAPAs, and change controls.<\/p>\n

The FDA report additionally flagged bacterial contaminations and pest infestations.<\/p>\n

For years, the plant also fielded complaints from different clients regarding \u201cforeign matter\u201d detected in lots produced at the facility.<\/p>\n

The site also \u201cfailed to investigate all critical equipment failures that have the potential to impact drug products,\u201d the agency investigation revealed.<\/p>\n

Between late February 2024 and May 2025, the plant opened roughly 10 work orders for \u201crecurrent leaks and\/or other failures\u201d of a certain system, for which some repairs were substantially delayed.<\/p>\n

In 2022, Catalent\u00a0received an FDA write-up for its syringe filling facility in Belgium, \u201callegedly\u201d the culprit behind the supply shortage for\u00a0Novo Nordisk\u2019s obesity drug Wegovy<\/a>.<\/p>\n

Regulatory concerns extend beyond Novo Nordisk. Regeneron Pharmaceuticals Inc. REGN recently warned that FDA approvals for its EYLEA HD applications, covering pre-filled syringes and expanded dosing schedules, may be pushed back.<\/p>\n

The company pointed to FDA observations from a general site inspection at Catalent\u2019s Indiana filler, which is responsible for the EYLEA HD lots tied to those submissions. The applications have Prescription Drug User Fee Act (PDUFA)<\/a> dates in August 2025.<\/p>\n

Price Action: NVO stock is trading lower by 0.32% to $56.80 at last check Monday.<\/p>\n

Read Next:<\/p>\n

Image via Shutterstock<\/p>\n","protected":false},"excerpt":{"rendered":"The U.S. Food and Drug Administration (FDA) has identified repeated quality control failures, including foreign particle contamination, inadequate…\n","protected":false},"author":2,"featured_media":95448,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[64,63,8331,70329,8335,8334,8332,70330,8333,38214,8330,137,500,8329,70331,62109,70332,70333],"class_list":["post-95447","post","type-post","status-publish","format-standard","has-post-thumbnail","category-healthcare","tag-au","tag-australia","tag-category-biotech","tag-category-fda","tag-category-general","tag-category-health-care","tag-category-large-cap","tag-category-movers","tag-category-news","tag-category-top-stories","tag-cms-wordpress","tag-health","tag-healthcare","tag-pageisbzpro-bz","tag-symbol-ctlt","tag-symbol-nvo","tag-symbol-regn","tag-tag-why-its-moving"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/95447","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/comments?post=95447"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/95447\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media\/95448"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media?parent=95447"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/categories?post=95447"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/tags?post=95447"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}